Calcium phosphate-based materials containing zinc, magnesium, fluoride and carbonate
US-9199005-B2 · Dec 1, 2015 · US
US2016287632A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016287632-A1 |
| Application number | US-201514962889-A |
| Country | US |
| Kind code | A1 |
| Filing date | Dec 8, 2015 |
| Priority date | Sep 21, 2007 |
| Publication date | Oct 6, 2016 |
| Grant date | — |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Provided are methods and kits for safe and effective therapy that can be administered early after a heart attack in order to prevent progressive heart dilatation and resultant loss of function. The therapy includes the administration of particulate compositions to a region comprising an infarct or a portion thereof.
Opening claim text (preview).
1 .- 16 . (canceled) 17 . A kit for use in the stabilization of cardiac infarct tissue comprising: a composition comprising a biologically compatible, acellular material comprising particles having characteristic dimensions of 25 μm to about 50 μm; and, an injection tool capable of delivering said composition directly into a cardiac infarct itself, and optionally into a region of tissue containing the infarct, into tissue adjacent to or partially or completely surrounding the infarct, or both within a living patient. 18 . The kit according to claim 17 wherein said material comprises microparticles of one or more forms of calcium phosphate. 19 . The kit according to claim 17 wherein said composition comprises a suspension of said microparticles in an aqueous carrier. 20 . The kit according to claim 17 wherein said injection tool comprises a catheter. 21 . The kit according to claim 17 wherein said composition is provided in one or more premeasured aliquots. 22 .- 25 . (canceled)
for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title
Flowable or injectable implant compositions · CPC title
Phosphorus-containing materials, e.g. apatite · CPC title
Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)} · CPC title
Ceramics or glasses · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.